JCR Pharmaceuticals Co., Ltd.

Tokyo Stock Exchange 4552.T

JCR Pharmaceuticals Co., Ltd. EBITDA Margin for the year ending March 31, 2024: 24.56%

JCR Pharmaceuticals Co., Ltd. EBITDA Margin is 24.56% for the year ending March 31, 2024, a 20.93% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

JCR Pharmaceuticals Co., Ltd. EBITDA Margin for the year ending March 31, 2023 was 20.31%, a -52.59% change year over year.
JCR Pharmaceuticals Co., Ltd. EBITDA Margin for the year ending March 31, 2022 was 42.83%, a 26.57% change year over year.
JCR Pharmaceuticals Co., Ltd. EBITDA Margin for the year ending March 31, 2021 was 33.84%, a 79.23% change year over year.
JCR Pharmaceuticals Co., Ltd. EBITDA Margin for the year ending March 31, 2020 was 18.88%, a -30.71% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 4552.T

JCR Pharmaceuticals Co., Ltd.

CEO	Mr. Shin Ashida
IPO Date	Nov. 17, 2005
Location	Japan
Headquarters	3-19 Kasuga-cho
Employees	934
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Key trends

Past 5 years